Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Community-based exercise for health promotion and secondary cancer prevention in Canada: protocol for a hybrid effectiveness-implementation study.

McNeely ML, Sellar C, Williamson T, Shea-Budgell M, Joy AA, Lau HY, Easaw JC, Murtha AD, Vallance J, Courneya K, Mackey JR, Parliament M, Culos-Reed N.

BMJ Open. 2019 Sep 13;9(9):e029975. doi: 10.1136/bmjopen-2019-029975.

2.

Accuracy of Resting Energy Expenditure Predictive Equations in Patients With Cancer.

Purcell SA, Elliott SA, Baracos VE, Chu QSC, Sawyer MB, Mourtzakis M, Easaw JC, Spratlin JL, Siervo M, Prado CM.

Nutr Clin Pract. 2019 Dec;34(6):922-934. doi: 10.1002/ncp.10374. Epub 2019 Jul 25.

PMID:
31347209
3.

Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors.

Coppens R, Yang J, Ghosh S, Gill J, Chambers C, Easaw JC.

J Oncol Pharm Pract. 2019 Sep;25(6):1366-1373. doi: 10.1177/1078155218792985. Epub 2018 Aug 19.

PMID:
30124122
4.

Management of Medical Oncology Services in Canada: Redefined Workload With a Novel Supply-and-Demand Workforce Projection Model.

Yip SM, Loewen SK, Li H, Hao D, Easaw JC.

J Oncol Pract. 2018 Jul;14(7):e438-e445. doi: 10.1200/JOP.18.00114.

PMID:
29996073
5.

ClotAssist: A program to treat cancer-associated thrombosis in an outpatient pharmacy setting.

Easaw JC, McCall S, Azim A.

J Oncol Pharm Pract. 2019 Jun;25(4):818-823. doi: 10.1177/1078155218760704. Epub 2018 Mar 14.

PMID:
29540105
6.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R.

JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.

7.

PO-42 - A novel approach to a common problem: after-hours care of cancer patients diagnosed with VTE.

Easaw JC, Azim A, McCall S, Huiser T, Lim S.

Thromb Res. 2016 Apr;140 Suppl 1:S192. doi: 10.1016/S0049-3848(16)30175-X. Epub 2016 Apr 8.

PMID:
27161732
8.

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL.

Clin Cancer Res. 2016 Aug 1;22(15):3860-75. doi: 10.1158/1078-0432.CCR-15-1798. Epub 2016 Mar 22.

9.

Association between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastoma.

Liu RZ, Li S, Garcia E, Glubrecht DD, Poon HY, Easaw JC, Godbout R.

Glia. 2016 Jun;64(6):963-76. doi: 10.1002/glia.22976. Epub 2016 Feb 19.

10.

Pseudoprogression in a Patient With Glioblastoma Presenting as a Neurosurgical Emergency.

Sayeed WM, Easaw JC, Singh AD.

Can J Neurol Sci. 2015 Sep;42(5):347-9. doi: 10.1017/cjn.2015.53. Epub 2015 Jul 29. No abstract available.

PMID:
26219577
11.

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.

Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, MacNeil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, Tagalakis V, Welch S, Kavan P.

Curr Oncol. 2015 Apr;22(2):144-55. doi: 10.3747/co.22.2587.

12.

Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.

Easaw JC, Shea-Budgell MA, Wu CM, Czaykowski PM, Kassis J, Kuehl B, Lim HJ, MacNeil M, Martinusen D, McFarlane PA, Meek E, Moodley O, Shivakumar S, Tagalakis V, Welch S, Kavan P.

Curr Oncol. 2015 Apr;22(2):133-43. doi: 10.3747/co.22.2586.

13.

Phase II study of PX-866 in recurrent glioblastoma.

Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP.

Neuro Oncol. 2015 Sep;17(9):1270-4. doi: 10.1093/neuonc/nou365. Epub 2015 Jan 20.

14.

Population based analysis ependymoma patients in Alberta from 1975 to 2007.

Roldán Urgoiti GB, Singh AD, Tsang RY, Nordal RA, Lim G, Chan JA, Starreveld YP, de Robles PA, Biagioni BJ, Hamilton MG, Easaw JC.

Can J Neurol Sci. 2014 Nov;41(6):742-7. doi: 10.1017/cjn.2014.107. Epub 2014 Nov 10.

PMID:
25382385
15.

Evidence-based guidance on venous thromboembolism in patients with solid tumours.

Shea-Budgell MA, Wu CM, Easaw JC.

Curr Oncol. 2014 Jun;21(3):e504-14. doi: 10.3747/co.21.1938.

16.

Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.

Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ; NCIC Clinical Trials Group; Australasian Gastrointestinal Trials Group.

Cancer. 2014 Jan 15;120(2):181-9. doi: 10.1002/cncr.28410. Epub 2013 Oct 11.

17.

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).

Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.

J Med Econ. 2013 Dec;16(12):1387-98. doi: 10.3111/13696998.2013.852097. Epub 2013 Oct 25.

PMID:
24102083
18.

Management of recurrent medulloblastoma in adult patients: a systematic review and recommendations.

Kostaras X, Easaw JC.

J Neurooncol. 2013 Oct;115(1):1-8. doi: 10.1007/s11060-013-1206-3. Epub 2013 Jul 23. Review.

PMID:
23877361
19.

O6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.

Chahal M, Abdulkarim B, Xu Y, Guiot MC, Easaw JC, Stifani N, Sabri S.

Mol Cancer Ther. 2012 Nov;11(11):2440-50. doi: 10.1158/1535-7163.MCT-11-0977. Epub 2012 Sep 17.

20.

Chemotherapy-associated steatohepatitis with temozolomide and dexamethasone.

Miller RJ, Gui X, Easaw JC, Tsang RY.

Can J Neurol Sci. 2012 Jul;39(4):547-9. No abstract available.

PMID:
22896875
22.

Lipidized glioblastoma: pathological and molecular characteristics.

Singh AD, Iftinca M, Easaw JC.

Neuropathology. 2013 Feb;33(1):87-92. doi: 10.1111/j.1440-1789.2012.01326.x. Epub 2012 May 29.

PMID:
22640269
23.

Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.

Roldán Urgoiti GB, Singh AD, Easaw JC.

J Neurooncol. 2012 May;108(1):173-7. doi: 10.1007/s11060-012-0826-3. Epub 2012 Mar 2.

PMID:
22382781
24.

Is there a role for clinical practice guidelines in multidisciplinary tumor board meetings? A descriptive study of knowledge transfer between research and practice.

Kostaras X, Shea-Budgell MA, Malcolm E, Easaw JC, Roa W, Hagen NA.

J Cancer Educ. 2012 Mar;27(1):42-5. doi: 10.1007/s13187-011-0263-6.

PMID:
21882052
25.

Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Easaw JC, Mason WP, Perry J, Laperrière N, Eisenstat DD, Del Maestro R, Bélanger K, Fulton D, Macdonald D; Canadian Glioblastoma Recommendations Committee.

Curr Oncol. 2011 Jun;18(3):e126-36.

26.

Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.

Hamilton MG, Roldán G, Magliocco A, McIntyre JB, Parney I, Easaw JC.

J Neurooncol. 2011 Apr;102(2):255-60. doi: 10.1007/s11060-010-0307-5. Epub 2010 Jul 21.

PMID:
20652362
27.

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

Roldán GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, Yan ES, Parney IF, Forsyth PA, Cairncross JG, Hamilton MG, Easaw JC.

Can J Neurol Sci. 2009 Sep;36(5):617-22.

PMID:
19831132
28.

Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.

Vickers MM, Easaw JC.

J Gastrointest Cancer. 2008;39(1-4):141-3. doi: 10.1007/s12029-009-9068-9. Epub 2009 May 14.

PMID:
19440857
29.

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

Sijben AE, McIntyre JB, Roldán GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG.

J Neurooncol. 2008 Aug;89(1):97-103. doi: 10.1007/s11060-008-9593-6. Epub 2008 Apr 9.

PMID:
18398569
30.

Zinc modulation of ionic currents in the horizontal limb of the diagonal band of Broca.

Easaw JC, Jassar BS, Harris KH, Jhamandas JH.

Neuroscience. 1999;94(3):785-95.

PMID:
10579569
32.

An electrophysiological study of neurons in the horizontal limb of the diagonal band of Broca.

Easaw JC, Petrov T, Jhamandas JH.

Am J Physiol. 1997 Jan;272(1 Pt 1):C163-72.

PMID:
9038822
33.

Glutamate receptor subtypes mediate excitatory synaptic responses of rat lateral parabrachial neurons.

Zidichouski JA, Easaw JC, Jhamandas JH.

Am J Physiol. 1996 May;270(5 Pt 2):H1557-67.

PMID:
8928860
35.

Modulation of sprouting in organ culture after axotomy of an identified molluscan neuron.

Berdan RC, Easaw JC.

J Neurobiol. 1992 Jun;23(4):433-50.

PMID:
1321884

Supplemental Content

Loading ...
Support Center